Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Deciphera Pharmaceuticals LLC (DCPH)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Deciphera Pharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
14.18 -0.44    -3.01%
25/04 - Closed. Currency in USD ( Disclaimer )
After Hours
14.18
-0.00
-0.00%
16:20:01 - Real-time Data
  • Volume: 441,376
  • Bid/Ask: 5.69 / 19.87
  • Day's Range: 14.00 - 14.73
Type:  Equity
Market:  United States
Deciphera Pharma 14.18 -0.44 -3.01%

Deciphera Pharmaceuticals LLC Company Profile

 
Get an in-depth profile of Deciphera Pharmaceuticals LLC, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

300

Equity Type

ORD

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Contact Information

Address 200 Smith Street
Waltham, 02451
United States
Phone 781 209 6400
Fax 785 830 2150

Top Executives

Name Age Since Title
Steven L. Hoerter 50 2018 President, CEO & Director
James A. Bristol 76 2007 Independent Director
John S. Condeelis - - Member of Scientific Advisory Board
Dennis Leo Walsh 55 2015 Independent Director
Jean-Yves Blay 61 2015 Member of Scientific Advisory Board
Ron Squarer 56 2019 Independent Chairman
Filip Janku 48 2015 Member of Scientific Advisory Board
Michele De Palma - - Member of Scientific Advisory Board
John de Groot - - Member of Scientific Advisory Board
Patricia L. Allen 61 2016 Independent Director
Frank S. Friedman 65 2019 Independent Director
F. Stephen Hodi - 2015 Member of Scientific Advisory Board
John R. Martin 62 2015 Independent Director
Edward J. Benz 77 2016 Independent Director
Susan L. Kelley 68 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DCPH Comments

Write your thoughts about Deciphera Pharmaceuticals LLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
ritchie donaghue
ritchie donaghue Feb 13, 2020 20:38
Saved. See Saved Items.
This comment has already been saved in your Saved Items
interesting day, new offering on the shirt tails of the path to august, hmmm
ritchie donaghue
ritchie donaghue Dec 17, 2019 12:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2 pipelines heading to approval
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email